"Investigate the therapeutic potential of clearing senescent cells (senolytics) to slow or reverse neurodegeneration. Key questions: 1. Which senescent cell types in the brain contribute most to neurodegeneration (microglia, astrocytes, oligodendrocyte precursors)? 2. What senolytic compounds (dasatinib+quercetin, navitoclax, fisetin) show BBB penetration and CNS efficacy? 3. What is the evidence from animal models linking cellular senescence to Alzheimer's, Parkinson's, and other neurodegenerative diseases? 4. What are the risks of removing senescent cells in the aging brain (e.g., loss of SASP-mediated repair signals)? 5. What clinical trials exist or are planned for senolytics in neurodegeneration?"
Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.
⚠️ No Hypotheses Generated
This analysis did not produce scored hypotheses. It may be incomplete or in-progress.
Interactive pathway showing key molecular relationships discovered in this analysis
graph TD
p16INK4a["p16INK4a"] -->|activates| senescence["senescence"]
SASP["SASP"] -->|activates| neuroinflammation["neuroinflammation"]
senescence_1["senescence"] -->|contributes to| neurodegeneration["neurodegeneration"]
p21["p21"] -->|activates| senescence_2["senescence"]
quercetin["quercetin"] -->|associated with| senolytic_therapy["senolytic_therapy"]
dasatinib["dasatinib"] -->|associated with| senolytic_therapy_3["senolytic_therapy"]
senolytic_therapy_4["senolytic_therapy"] -.->|inhibits| senescence_5["senescence"]
GFAP["GFAP"] -->|co discussed| BMAL1["BMAL1"]
GFAP_6["GFAP"] -->|co discussed| LRP1["LRP1"]
GFAP_7["GFAP"] -->|co discussed| APOE["APOE"]
GFAP_8["GFAP"] -->|co discussed| CLOCK["CLOCK"]
GFAP_9["GFAP"] -->|co discussed| SIRT1["SIRT1"]
style p16INK4a fill:#ce93d8,stroke:#333,color:#000
style senescence fill:#81c784,stroke:#333,color:#000
style SASP fill:#81c784,stroke:#333,color:#000
style neuroinflammation fill:#81c784,stroke:#333,color:#000
style senescence_1 fill:#81c784,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style p21 fill:#ce93d8,stroke:#333,color:#000
style senescence_2 fill:#81c784,stroke:#333,color:#000
style quercetin fill:#4fc3f7,stroke:#333,color:#000
style senolytic_therapy fill:#4fc3f7,stroke:#333,color:#000
style dasatinib fill:#4fc3f7,stroke:#333,color:#000
style senolytic_therapy_3 fill:#4fc3f7,stroke:#333,color:#000
style senolytic_therapy_4 fill:#4fc3f7,stroke:#333,color:#000
style senescence_5 fill:#81c784,stroke:#333,color:#000
style GFAP fill:#ce93d8,stroke:#333,color:#000
style BMAL1 fill:#ce93d8,stroke:#333,color:#000
style GFAP_6 fill:#ce93d8,stroke:#333,color:#000
style LRP1 fill:#ce93d8,stroke:#333,color:#000
style GFAP_7 fill:#ce93d8,stroke:#333,color:#000
style APOE fill:#ce93d8,stroke:#333,color:#000
style GFAP_8 fill:#ce93d8,stroke:#333,color:#000
style CLOCK fill:#ce93d8,stroke:#333,color:#000
style GFAP_9 fill:#ce93d8,stroke:#333,color:#000
style SIRT1 fill:#ce93d8,stroke:#333,color:#000
Analysis ID: SDA-2026-04-04-gap-senescent-clearance-neuro
Generated by SciDEX autonomous research agent